Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

141. Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time? Full Text available with Trip Pro

Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time? Hypertension is common in patients with chronic kidney disease (CKD) and is the most important modifiable risk factor for CKD progression and adverse cardiovascular events in these patients. Diagnosis and successful management of hypertension are critically dependent on accurate blood pressure (BP) measurement. This is most relevant to CKD patients, in whom BP control is difficult to achieve and in whom early (...) antihypertensive treatment is imperative to prevent kidney and cardiovascular complications. Accumulated data indicate that ambulatory blood pressure monitoring (ABPM) is better in detecting hypertension than office BP measurement. ABPM is also a superior prognostic marker compared with office BP and has successfully identified hypertensive CKD patients at increased risk. Additionally, ABPM provides information on circadian BP variation and short-term BP variability, which is associated with cardiovascular

2016 Kidney international reports

142. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. Full Text available with Trip Pro

Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. Patients with chronic kidney disease (CKD) are at an increased risk of cardiovascular disease (CVD) compared with the general population. Prior studies have produced contradictory results on the association of dietary sodium intake with risk of CVD, and this relationship has not been investigated in patients with CKD.To evaluate the association between urinary sodium excretion and clinical CVD (...) events among patients with CKD.A prospective cohort study of patients with CKD from 7 locations in the United States enrolled in the Chronic Renal Insufficiency Cohort Study and followed up from May 2003 to March 2013.The cumulative mean of urinary sodium excretion from three 24-hour urinary measurements and calibrated to sex-specific mean 24-hour urinary creatinine excretion.A composite of CVD events defined as congestive heart failure, stroke, or myocardial infarction. Events were reported every 6

2016 JAMA

143. Role of Bile Acid Regulated Nuclear Receptor FXR and G Protein Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease) Full Text available with Trip Pro

Role of Bile Acid Regulated Nuclear Receptor FXR and G Protein Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease) 27045028 2018 01 16 2018 12 02 1524-4563 67 6 2016 06 Hypertension (Dallas, Tex. : 1979) Hypertension Role of Bile Acid-Regulated Nuclear Receptor FXR and G Protein-Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease). 1080-4 10.1161/HYPERTENSIONAHA.115.06417 Levi (...) , Cytoplasmic and Nuclear 0 Receptors, G-Protein-Coupled 0C5V0MRU6P farnesoid X-activated receptor IM Animals Cardio-Renal Syndrome metabolism physiopathology therapy Diabetes Mellitus diagnosis metabolism Disease Progression Humans Lipid Metabolism drug effects Obesity diagnosis metabolism Prognosis Receptors, Cytoplasmic and Nuclear agonists physiology Receptors, G-Protein-Coupled agonists physiology 2016 4 6 6 0 2016 4 6 6 0 2018 1 18 6 0 ppublish 27045028 HYPERTENSIONAHA.115.06417 10.1161

2016 Hypertension (Dallas, Tex. : 1979)

144. Acute kidney injury and chronic kidney disease: from the laboratory to the clinic Full Text available with Trip Pro

chronic kidney disease appear to be less able to mount a complete 'adaptive' repair after acute insults, and instead repair maladaptively, with accelerated fibrosis and rates of renal functional decline. This article reviews the epidemiological studies in man that have demonstrated the links between these two processes. We also examine clinical and experimental research in areas of importance to both acute and chronic disease: acute and chronic renal injury to the vasculature, the pericyte (...) Acute kidney injury and chronic kidney disease: from the laboratory to the clinic Chronic kidney disease and acute kidney injury have traditionally been considered as separate entities with different etiologies. This view has changed in recent years, with chronic kidney disease recognized as a major risk factor for the development of new acute kidney injury, and acute kidney injury now accepted to lead to de novo or accelerated chronic and end stage kidney diseases. Patients with existing

2016 Nephrologie & therapeutique

145. Soluble Urokinase Receptor and Chronic Kidney Disease. Full Text available with Trip Pro

Soluble Urokinase Receptor and Chronic Kidney Disease. 26962914 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and Chronic Kidney Disease. 891 10.1056/NEJMc1515787 Hayek Salim S SS Quyyumi Arshed A AA Reiser Jochen J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9 (...) ):890 26962915 N Engl J Med. 2016 Mar 3;374(9):890 26962916 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962914 10.1056/NEJMc1515787 10.1056/NEJMc1515787#SA3

2016 NEJM

146. Soluble Urokinase Receptor and Chronic Kidney Disease. Full Text available with Trip Pro

Soluble Urokinase Receptor and Chronic Kidney Disease. 26962915 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and Chronic Kidney Disease. 890 10.1056/NEJMc1515787 Quaglia Marco M University of Piemonte Orientale, Novara, Italy claudio.musetti@med.uniupo.it. Musetti Claudio C University of Piemonte Orientale, Novara, Italy claudio.musetti@med.uniupo.it. Cantaluppi Vincenzo V University of Piemonte Orientale (...) , Novara, Italy claudio.musetti@med.uniupo.it. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9):891 26962914 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962915 10.1056/NEJMc1515787 10.1056

2016 NEJM

147. Soluble Urokinase Receptor and Chronic Kidney Disease. Full Text available with Trip Pro

Soluble Urokinase Receptor and Chronic Kidney Disease. 26962916 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and Chronic Kidney Disease. 890 10.1056/NEJMc1515787 Schumacher Martin M University of Freiburg Medical Center, Freiburg, Germany ms@imbi.uni-freiburg.de. Wanner Christoph C Würzburg University Clinic, Würzburg, Germany. Beyersmann Jan J University of Ulm, Ulm, Germany. eng Letter Comment United States N (...) Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9):891 26962914 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962916 10.1056/NEJMc1515787 10.1056/NEJMc1515787#SA2

2016 NEJM

148. Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study. (Abstract)

subgroups.Chronic kidney disease was identified by a single measurement at each visit.Overweight and obesity are associated with an increased incidence of CKD in metabolically healthy young and middle-aged participants. These findings show that metabolically healthy obesity is not a harmless condition and that the obese phenotype, regardless of metabolic abnormalities, can adversely affect renal function.None. (...) Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study. The risk for chronic kidney disease (CKD) among obese persons without obesity-related metabolic abnormalities, called metabolically healthy obesity, is largely unexplored.To investigate the risk for incident CKD across categories of body mass index in a large cohort of metabolically healthy men and women.Prospective cohort study.Kangbuk Samsung Health Study, Kangbuk Samsung Hospital, Seoul, South Korea.62

2016 Annals of Internal Medicine

149. Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease Full Text available with Trip Pro

Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease 27733948 2018 11 13 2147-9720 3 3 2016 Sep European journal of rheumatology Eur J Rheumatol Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease. 144-145 Oiwa Hiroshi H Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. Mokuda Sho S (...) Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Department of Immunology, Hiroshima University School of Biomedical and Health, Hiroshima, Japan. eng Journal Article 2016 01 29 Turkey Eur J Rheumatol 101656068 2147-9720 Dr. Oiwa reports personal fees from Daiichi Sankyo, during the conduct of the study. 2015 07 02 2015 08 01 2016 10 14 6 0 2016 10 14 6 0 2016 10 14 6 1 ppublish 27733948 10.5152/eurjrheum.2015.0049 ejr-3-3-144 PMC5058456 Am J Kidney Dis. 2009 Jun

2016 European journal of rheumatology

150. The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1 Full Text available with Trip Pro

The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1 28197495 2019 01 09 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol The modifiers of chronic kidney disease in autosomal dominant polycystic kidney disease and the role of the endothelin-1. 24-25 Einollahi Behzad B Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Lotfiazar Aidin A Nephrology and Urology (...) Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. eng Journal Article 2016 01 12 Iran J Nephropharmacol 101679372 2345-4202 Autosomal dominant polycystic kidney disease Chronic kidney disease Endothelin-1 2015 12 27 2016 01 10 2017 2 16 6 0 2017 2 16 6 0 2017 2 16 6 1 epublish 28197495 PMC5297502 Am J Kidney Dis. 1990 Nov;16(5):403-13 2239929 Iran J Kidney Dis. 2014 Jul;8(4):265-77 25001132 Lancet. 2007 Apr 14;369(9569):1287-301 17434405 J Am Soc Nephrol. 2013 May;24(6):1006

2016 Journal of nephropharmacology

151. Growth Monitoring for Children with Chronic Kidney Disease

). However the frequency of measurement we recommend provides significant benefits in our opinion but has a weak evidence base due to a general lack of studies in this area(1D). This guideline is endorsed by The British Society for Paediatric Endocrinology and Diabetes (BSPED), The British Association for Paediatric Nephrology (BAPN) and The Paediatric Renal Interest Nutrition Group (PRING). Stages of Chronic Kidney Disease (CKD) 14 Stage GFR* Description Management 1 > 90 Normal Renal Function (...) and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: a report of the Growth Failure in Children with Renal Diseases study. J Paediatr. 1990; 116: S46 – 54 2. Norman LJ, Coleman JE, MacDonald 1A, Thomsett AM, Watson AR: Nutrition and Growth in relation to severity of renal disease in children, Paediatric Nephrology 2000; 15, 259-65. 3. Kari JA, Gonzalez C, Lederman S, Shaw V, Rees L: Outcome and Growth of Infants with Severe Chronic Renal Failure. Kidney

2016 British Society for Paediatric Endocrinology and Diabetes

152. Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes

Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes Article Text Therapeutics/Prevention Systematic review with meta analysis Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes David W Johnson Statistics from Altmetric.com Commentary on: Cody JD , Hodson EM . Recombinant

2016 Evidence-Based Medicine

153. ERBP Guideline on Management of Older Patients with Chronic Kidney Disease Full Text available with Trip Pro

assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice ESKD End-stage kidney disease HD Hemodialysis HR Hazard ratio KFRE Kidney Failure Risk Equation MD Mean Difference MDRD Modification of Diet in Renal Disease OR Odds Ratio (...) PD Peritoneal dialysis QoL Quality of life RCT Randomized controlled trial REIN Renal Epidemiology and Information Network RR Relative Risk RRT Renal replacement therapy SGA Subjective global assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP

2016 European Renal Best Practice

154. What Is the Significance of Elevated Troponin in Patients With Suspected Acute Coronary Syndrome and Chronic Kidney Disease?

. Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure. Nefrologia. 2012;32:809-818. 2. Kanderian AS, Francis GS. Cardiac troponins and chronic kidney disease. Kidney Int. 2006;69:1112-1114. 3. Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome. Ann Intern Med.2014;161: 491-501. 4. Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I (...) among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112:3088-3096. 5. Amsterdam EZ, Wenger NK, Peterson ED, et al. 2014 AHA/ACC guideline for the management of patients with non-ST- elevation acute coronary syndromes.JAm Coll Cardiol. 2014;64:e139-228. 6. Acharji S, Baber U, Mehran R, et al. Prognostic signi?cance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney Systematic Review Snapshot 108 Annals of Emergency

2016 Annals of Emergency Medicine Systematic Review Snapshots

155. Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes Full Text available with Trip Pro

on Ethnicity, Culture and Health, School of Public Health, University of Michigan, Ann Arbor, MI, USA. eng R01 AG018418 AG NIA NIH HHS United States Editorial 2015 12 12 Iran J Nephropharmacol 101679372 2345-4202 Chronic kidney disease End stage renal disease Health disparities Socio-economics 2015 10 07 2015 12 05 2017 2 16 6 0 2015 12 12 0 0 2015 12 12 0 1 epublish 28197489 PMC5297505 Am J Mens Health. 2013 Jul;7(4 Suppl):58S-67S 23609347 J Diabetes Complications. 2003 Jan-Feb;17(1):39-58 12505756 Clin J (...) Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes 28197489 2018 11 13 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes. 4-6 Assari Shervin S Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA ; Center for Research

2015 Journal of nephropharmacology

156. Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients Full Text available with Trip Pro

Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the presence of numerous cysts in the kidney and manifest with various renal and extra-renal complications leading to ESRD. Endothelin may contribute to various renal and extra-renal manifestations pointing to genetic and environmental modifying factors that alter (...) the risk of developing chronic kidney disease (CKD) in ADPKD. In the present study we investigated six genes coding for endothelin 1 ( EDN1 ) tagging-single nucleotide polymorphisms (tag-SNPs) to unravel the EDN1 gene modifier effect for renal disease progression in ADPKD. Materials and Methods: The tag-SNPs were genotyped using FRET-based KASPar method in 108 ADPKD patients and 119 healthy subjects. Cochran-Armitage trend test was used to determine the association between ADPKD and EDN1 tag-SNPs

2015 Journal of nephropharmacology

157. Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD)

Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD) Sonidegib (Odomzo ® ) capsule Novartis Pharmaceuticals UK Ltd November 2015 Advice context: The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Care Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication

2015 All Wales Medicines Strategy Group

158. A suPAR Biomarker for Chronic Kidney Disease. (Abstract)

A suPAR Biomarker for Chronic Kidney Disease. 26539740 2015 11 23 2018 12 02 1533-4406 373 20 2015 Nov 12 The New England journal of medicine N. Engl. J. Med. A suPAR Biomarker for Chronic Kidney Disease. 1971-2 10.1056/NEJMe1512997 Skorecki Karl L KL From the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Rambam Health Care Campus, Haifa, Israel (K.L.S.); and the Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC (...) (B.I.F.). Freedman Barry I BI eng Editorial Comment 2015 11 05 United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2015 11 6 6 0 2015 11 6 6 0 2015 12 15 6 0 ppublish 26539740 10.1056/NEJMe1512997

2015 NEJM

159. Soluble Urokinase Receptor and Chronic Kidney Disease. Full Text available with Trip Pro

Soluble Urokinase Receptor and Chronic Kidney Disease. Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease.We measured (...) plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear mixed models and Cox

2015 NEJM

160. The double challenge of resistant hypertension and chronic kidney disease. (Abstract)

chronic kidney disease is associated with an impaired prognosis in patients with resistant hypertension. Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic, should be complemented by the sequential addition of other antihypertensive drugs. New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investigation especially in patients with advanced chronic kidney disease. We discuss resistant (...) The double challenge of resistant hypertension and chronic kidney disease. Resistant hypertension is defined as blood pressure above goal despite adherence to a combination of at least three optimally dosed antihypertensive medications, one of which is a diuretic. Chronic kidney disease is the most frequent of several patient factors or comorbidities associated with resistant hypertension. The prevalence of resistant hypertension is increased in patients with chronic kidney disease, while

2015 Lancet